Media and News
Twitter Feed
-
Huge paper from @VirusesImmunity et al. on #longcovid. The biggest risk factor is lower cortisol levels vs. control… https://t.co/JXj3TPIPPa -
What does biotech look like during recessions? Broadly speaking, over the past few decades, it's weakly correlated… https://t.co/W15fPKYB92
-
Multitasking in Spain https://t.co/DHCvZUukcQ
-
Biopharma IPOs plummeted in Q2 this year. Fewest IPOs and capital raised in years. $XBI https://t.co/xuNisNf0wB
-
RT @HelenBranswell: Yowza! The #monkeypox case count in the US jumped nearly 30% today. It went from 3591 to 4639, an increase of 1048… https://t.co/Kakw7qEW25
-
Really sad and disappointing article from @ScienceMagazine on a decades-long history of fabricated data and questio… https://t.co/BCOSwwZzNx
-
Latest working paper with @MazzucatoM at @IIPP_UCL about ARPA-H and how it can be improved by more funding, radical… https://t.co/zf9jrm0uCD
-
Q2 Aduhelm sales: $100k (vs. $22M in cost of sales for it.) Ouch. $BIIB https://t.co/vqMrv46o4u
-
Just the top 20 pharma company CEOs made over $300 million in total compensation last year (not including option ex… https://t.co/k8Dr98WCLP
-
Wowza! First image from JWST - galaxies 13 billion light years away. @NASA https://t.co/TP8WChgkoP
News
October 2019
Azitra Presents Data Showing Tolerability of its Lead Product Candidate ATR-04
April 2019
Azitra Demonstrates Feasibility of Engineering the Skin Microbiome to Treat Serious Skin Conditions
April 2019
March 2019
Azitra featured as “Company to Watch” by Life Science Leader
January 2019
September 2018
August 2018
Azitra Awarded NIH SBIR Grant to Develop Microbiome-based Therapeutic for Netherton Syndrome
April 2018
Article published in Cosmetics and Toiletries online. Read more here.
December 2017
November 2017
I was named one of the Forbes 30 Under 30 in Healthcare for 2018. Read more here, or here.
April 2017
Skin disease biotech Azitra closes $2.9M Series A for microbiome work